Haleon Dividend yield

Haleon is part of Pharmaceuticals and Biotechnology business, which is part of Health Care industry. Haleon is a company from UK, and his stocks are publicly traded.

Haleon stock dividend

Haleon paid a total dividend of 369 million GBP last year, for a market value of 29,829 millions (Market Cap 16,872 millions). Haleon dividend per share is 0.04 GBP, and his stock market price 3.23 GBP.

According to the chart below, where dividend yield is displayed, Haleon has a dividend yield of 1.30%, lower than the amount offered by both the market average and companies from UK. It is also lower than average of Health Care industry. This low dividend yield might has several explanations: company overpriced, expanding their business,...

In addition, you should compare Haleon stocks dividend with other Pharmaceuticals and Biotechnology companies or other of the highest UK dividend stocks list.

Haleon Dividend Payout

About the ability of Haleon to maintain his current dividend of GBP 0.04 per share, an amount that accounts for 1.30%, we should study its payout ratio both on earnings and on cash-flows (see chart below). Haleon payout on ernings is currently 30.77%, which is lower than the market average, but higher than companies of Health Care industry, which are 39.34% and 23.54% respectively. Both figures show that Haleon is in a good position to keep maintaining his dividend.

The payout on earnings should be complemented with the payout on cash flow since it is this last amount the one which can be distributed to shareholders. Cash flow per share of Haleon is GBP 0.21 per share, which is higher than the dividend per share paid by the company of GBP 0.04, so the company generates enough cash to maintain his dividend in the future.

The following figure shows payout ratios over earnings and cashflow of Haleon, compared againt world market average, UK companies, Health Care industry and Pharmaceuticals and Biotechnology sector companies.

Haleon Stock performance

Finally, last moth Haleon showed a return of -4.10% compared to a worldwide -2.49% average, and a -2.07% of Health Care firms. Over the last year, the company obtained a 24.60% versus a worldwide performance of a 8.71%. More detailed information can be seen in the following graph for UK and Pharmaceuticals and Biotechnology firms.